Business Context and Reporting Period
This Form 8-K Current Report was filed by NeuroBo Pharmaceuticals, Inc. on November 15, 2024. The filing documents a corporate name change from "NeuroBo Pharmaceuticals, Inc." to "MetaVia Inc." effective November 29, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and branding changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Legal Name Change: The company's legal name will change to "MetaVia Inc." effective November 29, 2024.
- Bylaws Amendment: The Board approved the Fourth Amended and Restated Bylaws to reflect the name change and technical updates, effective November 29, 2024.
- Shareholder Rights: The name change does not affect shareholder rights and did not require a shareholder vote under Delaware law.
Guidance, Outlook, and Other Events
- Ticker Symbol Change: The company announced that its common stock will cease trading under the symbol "NRBO" and begin trading under the new symbol "MTVA" on November 29, 2024.
- Corporate Website: A new corporate website, metaviatx.com, is scheduled to launch on November 29, 2024, to host investor relations information.
- Forward-Looking Statements: The press release referenced in the filing contains forward-looking statements subject to risks and uncertainties; actual results may differ materially.
Investor Verification Checklist
- Verify the effective date of the ticker symbol change to "MTVA" on November 29, 2024.
- Confirm the launch of the new corporate website at metaviatx.com.
- Review the Fourth Amended and Restated Bylaws (Exhibit 3.2) for any technical changes beyond the name update.
- Check subsequent filings for the first financial report issued under the new "MetaVia Inc." name.